Sustained Response to Combined BRAF and MEK Inhibition in Colorectal Cancer with BRAF Mutation: A Case Study
By
Michela Guardascione
Monica Rizzetto
Luisa Foltran
Paola Di Nardo
Marco de Scordilli
Elena Ongaro
Arianna Fumagalli
Anna Calabrò
Andrea Botticelli
Paolo Marchetti
Fabio Puglisi
July 16, 2026
Clinical Scorecard: Sustained Response to Combined BRAF and MEK Inhibition in Colorectal Cancer with BRAF Mutation: A Case Study
At a Glance
Category Detail
Condition BRAF V600E-mutant metastatic colorectal cancer (BRAF mCRC) Key Mechanisms Combination of BRAF inhibitors and MEK inhibitors to block downstream signaling. Target Population Patients with BRAF V600E mutation in metastatic colorectal cancer. Care Setting Clinical trial setting for targeted therapy.
Key Highlights
Patient maintained stable disease for nearly four years on MEKi-based treatment. First-line treatment included FOLFOXIRI plus bevacizumab, followed by BRAF and MEK inhibitors. Documented longest response to MEKi-based regimen in BRAF mCRC. Personalized genomic profiling guided treatment decisions. No grade ≥ 3 adverse events reported during treatment. Guideline-Based Recommendations
Diagnosis
Molecular characterization for BRAF V600E mutation in mCRC patients. Management
Consideration of BRAF and MEK inhibitors in treatment regimens for BRAF mCRC. Monitoring & Follow-up
Regular imaging and tumor marker assessments to monitor disease progression. Risks
Potential for grade ≥ 3 adverse events with targeted therapies. Patient & Prescribing Data
Patients with BRAF V600E-mutant metastatic colorectal cancer.
Vemurafenib and cobimetinib combination showed prolonged progression-free survival.
Clinical Best Practices
Utilize personalized genomic profiling to inform treatment decisions. Monitor for adverse events and adjust dosing as necessary. Related Resources & Content
